Exactly. This makes CV-19 a real potential to meet both uplist requirements. We are already seeing the impact of what can happen with good results AND some media exposure. If leronlimab continues to get results and approval, money should follow one way or another (whether this be government loan, debt financing, etc.)...they will need capital for production, but should generate some revenues to hopefully meet the uplist cash requirement.